NaviAid 2: Depth of Maximal Ileal Insertion During Retrograde Enteroscopy With TTS Balloon

Sponsor
Texas Tech University Health Sciences Center, El Paso (Other)
Overall Status
Recruiting
CT.gov ID
NCT04646083
Collaborator
(none)
100
1
34.5
2.9

Study Details

Study Description

Brief Summary

Diagnostic modalities for the evaluation of small bowel pathology include video capsule endoscopy (VCE), antegrade and retrograde device-assisted enteroscopy, CT and MR enterography (1). Despite VCE being the first-line evaluation modality, it lacks interventional capability. Deep enteroscopy (DE) allows tissue sampling and other therapeutic interventions with real-time endoscopic assessment. DE is usually performed with specific endoscopes (balloon-assisted device or spiral overtube) making it time consuming and there is limited availability since special instruments and accessories are required.(1,2) The through-the-scope (TTS) balloon system consists of a balloon catheter designed for anchoring in the small bowel, inserted through the instrument channel of a standard colonoscope.(3) The catheter is advanced, the balloon is inflated and anchored in the small intestine and the endoscope slides over the guiding catheter to the inflated balloon. The most common indications for DE are obscure GI bleeding, iron deficiency anemia, abnormal capsule endoscopy and chronic diarrhea. As compared to spiral, single-or double-balloon enteroscopy, TTS (NaviAid, SMART Medical Systems Ltd, Ra'anana, Israel) is a simpler technique, which requires less investment in infrastructure. The balloon catheter is advanced blindly in front of a standard adult colonoscope as it bends around the curves of the small bowel. To prevent perforation/trauma the catheter is fitted with a soft silicone tip which easily bends under pressure.

Insertion depth can be calculated during the withdrawal of the enteroscope. The Aim of the study: To compare the depth of maximal ileal insertion between through-the-scope balloon enteroscopy (NaviAid) with enteroscopy using the adult colonoscope (Olympus CF-190) alone, in the same patient, in a prospective cohort at University Medical Center of El Paso, Texas.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The Aim of the study: To compare the depth of maximal ileal insertion between through-the-scope balloon enteroscopy (NaviAid) with enteroscopy using the adult colonoscope (Olympus CF-190) alone, in the same patient, in a prospective cohort from August 1, 2020 to July 31, 2023 at University Medical Center of El Paso, Texas.

    Depth of insertion is correlated with diagnostic yield, meaning that we would like to ascertain if the use of the colonoscope with NaviAid will result in greater depth of insertion and potentially more findings of small bowel abnormalities than using a colonoscope alone.

    It is assumed that this is the case, but we want to show it and quantify it.

    HYPOTHESIS:

    The depth of ileal insertion is greater with the use of through-the-scope balloon enteroscopy (NaviAid) when compared with enteroscopy using the standard adult colonoscope (Olympus CF-190) alone.

    OBJECTIVE:

    To compare the depth of maximal ileal insertion between through-the-scope balloon enteroscopy (NaviAid) with the adult colonoscope (Olympus CF-190) alone, in the same patient, in a prospective cohort at University Medical Center of El Paso, Texas.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Depth of Maximal Insertion During Retrograde Enteroscopy Using Colonoscopy With Through-the-scope Balloon Enteroscopy (NaviAid) Compared With Using the Standard Colonoscope Alone
    Actual Study Start Date :
    Jan 14, 2021
    Anticipated Primary Completion Date :
    Dec 1, 2023
    Anticipated Study Completion Date :
    Dec 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. depth of maximal insertion into ileum [during the enteroscopy of the patient, about one hour]

      depth of insertion is measured on withdrawal of colonoscope by estimating in 10 cm intervals

    Secondary Outcome Measures

    1. diagnostic yield of retrograde enteroscopy [during the enteroscopy of the patient, bout one hour]

      proportion of studies with significant findings on enterosocpy

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Sign Informed Consent Form

    2. Patients age between 18-90 years

    3. Patients in which retrograde enteroscopy is indicated for any of the following:

    abnormal video capsule endoscopy non-diagnostic upper and lower endoscopy obscure gastrointestinal bleeding iron deficiency anemia non-diagnostic upper endoscopy and abnormal CT Hemodynamically stable

    Exclusion Criteria:
    1. Inability to sign Informed Consent Form

    2. Pregnancy and breast feeding

    3. Prior colon resection

    4. Patients with known strictures

    5. Patients with altered anatomy

    6. Inadequate bowel preparation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Texas Tech University Health Science Center El Paso El Paso Texas United States 79905

    Sponsors and Collaborators

    • Texas Tech University Health Sciences Center, El Paso

    Investigators

    • Principal Investigator: Marc J Zuckerman, MD, Texas Tech University Health Sciences Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Marc Zuckerman, Professor of Medicine, Texas Tech University Health Sciences Center, El Paso
    ClinicalTrials.gov Identifier:
    NCT04646083
    Other Study ID Numbers:
    • E20147
    First Posted:
    Nov 27, 2020
    Last Update Posted:
    Mar 31, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Marc Zuckerman, Professor of Medicine, Texas Tech University Health Sciences Center, El Paso
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 31, 2022